EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib‐Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency

Jiali Huang, Xiankang Zhang, Hui Zhang, Yu Li, Huidan Huang, Zhiyu Li, Zhixia Qiu, Hongxi Wu, Dechun Huang, Xi Xu, Jinlei Bian iD

Advanced Science · 2025

DOI: 10.1002/advs.202411479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jiali Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, Jiangsu, 210009,…. Hauptthemen laut MEDLINE: Lung Neoplasms, Glutaminase, Glutamine, Acrylamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province for Excellent Young Scientists, "Double First-Class" university project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overcoming acquired resistance to Osimertinib remains a critical challenge in treating NSCLC. This research indicates that Osimertinib‐resistant cells exhibit a strong dependence on glutamine metabolism. However, targeting GLS1 shows limited anticancer effects, probably because it cannot fully block the glutamine metabolic pathway. The investigation reveals that a more effective strategy involves simultaneously inhibiting both ASCT2 and GLS1. After confirming the efficacy of this dual‐targeting approach against Osimertinib‐resistant cells in preclinical models, the potential of utilizing a broad‐spectrum glutamine metabolism antagonist is further explored to achieve superior antitumor efficacy. DON, broad‐spectrum glutamine antagonist, presents toxicity issues. Herein, the high NQO1 expression in Osimertinib‐resistant NSCLC cells is leveraged to design an NQO1‐responsive DON prodrug, 10e (LBJ‐10e). This prodrug demonstrates superior safety compared to natural DON and greater antitumor activity against resistant tumors compared to the clinical phase II drug DRP104. These findings may address the clinical limitations of GLS1 allosteric inhibitors and underscore prodrug strategies in effectively treating Osimertinib‐resistant lung cancer, providing a foundation for future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsGlutaminaseGlutamineAcrylamidesAniline CompoundsDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungHumansMiceAnimalsCell Line, TumorXenograft Model Antitumor AssaysAntineoplastic AgentsMice, NudeIndolesPyrimidines

Stichwörter der Autor:innen

NQO1NSCLCOsimertinib resistancedrug designglutamine

Substanzen

osimertinibGlutaminaseGlutamineAcrylamidesAniline CompoundsAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
  • Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
  • Center of Drug Screening & Evaluation, Wannan Medical College, Wuhu, Anhui, 241000, China.

ORCID-Profile: Jinlei Bian

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province for Excellent Young Scientists
  • "Double First-Class" university project

Zitieren

APA

Huang, J., Zhang, X., Zhang, H., Li, Y., Huang, H., Li, Z., Qiu, Z., Wu, H., Huang, D., Xu, X., & Bian, J. (2025). Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib‐Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency. Advanced Science. https://doi.org/10.1002/advs.202411479

Vancouver

Huang J, Zhang X, Zhang H, Li Y, Huang H, Li Z, et al. Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib‐Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency. Advanced Science. 2025. doi:10.1002/advs.202411479

BibTeX
@article{Huang2025,
  author = {Huang, Jiali and Zhang, Xiankang and Zhang, Hui and Li, Yu and Huang, Huidan and Li, Zhiyu and Qiu, Zhixia and Wu, Hongxi and Huang, Dechun and Xu, Xi and Bian, Jinlei},
  title = {Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib‐Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202411479}
}
Kostenlos starten →